Impact of methylprednisolone treatment on the expression of macrophage inflammatory protein 3α and B lymphocyte chemoattractant in serum of multiple sclerosis patients

Pharmacological Reports

Volumn 60, Issue 4, 2008, Pages 549-554

  Michałowska Wender, Grazyna ^a,b   Losy, Jacek ^a,b   Biernacka Łukanty, Justyna ^b   Wender, Mieczysław ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

CXCL13; Methylprednisolone; MIP 3 ; Multiple sclerosis

Indexed keywords

CXCL13 CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LONG TERM CARE; MALE; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE RISK; RELAPSE;

EID: 52049126847     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Airla N, Luomala M, Elovaara I, Kettunen E, Knuutila S, Lehtimaki T: Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis. Preliminary results. J Neurol, 2004, 251, 1215-1219.
2. Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP, Yong VW et al.: Determinants of human B cell migration across brain endothelial cells. J Immunol, 2003, 170, 4497-4505.
3. Bartosik-Psujek H, Stelmasiak Z: Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse. Eur Neurol, 2004, 52, 237-241.
4. Diem R, Hobom M, Maier K, Weissert R, Storch MK, Meyer R, Bahr M: Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci, 2003, 23, 6993-7000.
5. Elovaara I, Ukkonen M, Leppakynas M, Lehtimaki T, Luomala M, Peltola J, Dastidar P: Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch Neurol, 2000, 57, 546-551.
6. Hodge G, Hodge S, Reynolds PN, Holmes M: Up-regulation of interleukin-8, interleukin-10, monocyte chemotactic protein-1, and monocyte chemotactic protein-3 in peripheral blood monocytes in stable lung transplant recipients: Are immunosuppression regimens working? Transplantation, 2005, 19, 387-391.
7. Humm AM, Z'Graggen WJ, Bühler R, Magistris MR, Rössler KM: Quantification of central motor conduction deficits in multiple-sclerosis patients before and after treatment of acute exacerbation by methylprednisolone, J Neurol Neurosurg Psychiatry, 2006, 77, 345-350.
8. Kochler RE, Caon AC, Willenborg DO, Clark-Lewis I, McColl SR: A role for macrophage inflammatory protein-3α/CC chemokine ligand 20 in immune priming during T cell-mediated inflammation of the central nervous system. J Immunol, 2003, 170, 6298-6306.
9. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, Hofbauer M et al.: Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain, 2006, 1219, 200-211.
10. Krzysiek R, Lefevre EA, Bernard J, Foussat A, Galanaud P, Lauache F, Richard Y: Regulation of CCR6 chemokine. receptor expression and responsiveness to macrophage inflammatory protein-3α/CCL20 in human B cells. Blood, 2000, 96, 2338-2345.
11. Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold R: High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol, 2001, 58, 91-97.
12. Liao F, Shirakawa AK, Foley J, Rabin R, Farber J: Human B cells become highly responsive to macrophage-inflammatory protein-3α/CC chemokine ligand-20 after cellular activation without changes in CCR6 expression or ligand binding. J Immunol, 2002, 168, 4871-4880.
13. Mc Donald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol, 2001, 50, 121-127.
14. Michałowska-Wender G, Losy J, Szczuciński A, Biernacka-Łukanty J, Wender M: Effect of methylprednisolone treatment on expression of sPECAM-1 and CXCL10 chemokine in serum of MS patients. Pharmacol Rep, 2006, 59, 920-923.
15. Michałowska-Wender G, Losy J, Wender M, Januszkiewicz-Lewandowska D, Nowak J: Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers. Pol J Pharmacol, 2003, 55, 877-880.
16. Mirowska D, Wicha W, Członkowski A, Członkowska A, Weber F: Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone, J Neuroimmunol, 2004, 146, 171-175.
17. Wang HY, Matsui M, Araya S, Onai N, Matsushima K, Saida T: Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis. J Neurol Sci, 2003, 216, 61-66.